Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

1(11%)

Results Posted

17%(1 trials)

Terminated

1(11%)

Phase Distribution

Ph phase_2

11%

Ph phase_4

56%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 2Efficacy & side effects

1(16.7%)

Phase 4Post-market surveillance

5(83.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(6)

Terminated(1)

Other(1)

Detailed Status

Completed6

Recruiting1

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (16.7%)

Phase 45 (83.3%)

Trials by Status

completed667%

recruiting111%

terminated111%

unknown111%

Recent Activity

1 active trials

Showing 5 of 9

completedphase_4

Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial

NCT06653634

unknown

Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

NCT05702879

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT03915964Phase 4

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Completed

NCT04086745Phase 4

A Study of Baricitinib in Participants With Rheumatoid Arthritis

Completed

NCT05080218Phase 4

COVID-19 VaccinE Response in Rheumatology Patients

Completed

NCT06653634Phase 4

Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial

Recruiting

NCT05702879

Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

Unknown

NCT04798287

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

Completed

NCT04772248

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints

Completed

NCT04953871Phase 4

Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis

Completed

NCT02862574Phase 2

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Terminated

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9